Large- and small-molecule inhibitors of transforming growth factor-β signaling

Current Opinion in Investigational Drugs

Volumn 7, Issue 6, 2006, Pages 513-521

  Akhurst, Rosemary J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti TGF therapy; Cancer; Drugs; Individualized medicine; TGF ; TGF inhibition

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AP 12009; GC 1008; GROWTH INHIBITOR; HTS 466284; LERDELIMUMAB; LY 2109761; LY 2157299; LY 364947; LY 550410; LY 580276; METELIMUMAB; MONOCLONAL ANTIBODY 1D11.16; NAFB 001; NAKED DNA; P 144; SB 505124; SD 208; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; CANCER CELL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SYNTHESIS; DRUG TARGETING; GENETIC VARIABILITY; GERM LINE; GLIOBLASTOMA; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; IMMUNOCOMPETENT CELL; LIGAND BINDING; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PATIENT SELECTION; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; SCAR FORMATION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SOMATIC MUTATION; STROMA CELL; SURVIVAL RATE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PATIENT SELECTION; PTERIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33745146191     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Roberts AB, Wakefield LM: The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA (2003) 100(15):8821-8623.
2. Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer (2003) 3(11):807-821.
3. Derynck R, Akhurst RJ, Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet (2001) 29(2):117-129.
4. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ: Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-β. Science (1990) 248(4963):1658-1660.
5. Geiser AG, Kim SJ, Roberts AB, Sporn MB: Characterization of the mouse transforming growth factor-β 1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol (1991) 11(1):84-92.
6. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB: Transforming growth factor β 1 positively regulates its own expression in normal and transformed cells. J Biol Chem (1988) 263(16):7741-7746.
7. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y et al: Circulating transforming growth factor β 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res (2001) 7(5):1258-1262.
8. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-β in patients with metastatic prostatic carcinoma. J Urol (1999) 161(1):182-187.
9. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, Allen-Mersh TG: Increased serum transforming growth factor-β1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin Exp Immunol (2003) 134(2):270-278.
10. Harada M, Tatsugami K, Nomoto M, Nomoto K: Circulating immunoglobulin-bound transforming growth factor β at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells. Clin Exp Immunol (2002) 128(2):204-212.
11. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature (2003) 425(6958):577-584.
12. Hocevar BA, Brown TL, Howe PH: TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J (1999) 18(5):1345-1356.
13. Yu L, Hebert MC, Zhang YE: TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J (2002) 21(14):3749-3759.
14. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G et al: TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev (2005) 19(22):2668-2681.
15. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV: Secreted transforming growth factor β2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA (2004) 101(18):7112-7117.
16. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL: Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 12(1):27-36.
17. Edlund S, Landstrom M, Heldin CH, Aspenstrom P: Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell (2002) 13(3):902-914.
18. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL: Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 275(47):36803-36810.
19. Vinals F, Pouyssegur J: Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol Cell Biol (2001) 21(21):7218-7230.
20. Yi JY, Shin I, Arteaga CL: Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem (2005) 280(11):10870-10876.
21. 1 arrest. Genes Dev (2000) 14(24):3093-3101.
22. Sirard C, Kim S, Mirtsos C, Tadich P, Hoodless PA, Itie A, Maxson R, Wrana JL, Mak TW: Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor β-related signaling. J Biol Chem (2000) 275(3):2063-2070.
23. Fink SP, Mikkola D, Willson JK, Markowitz S: TGF-β-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene (2003) 22(9):1317-1323.
24. Fink SP, Swinler SE, Lutterbaugh JD, Massague J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S: Transforming growth factor-β-induced growth inhibition in a Smad4 mutant colon adenoma cell line. Cancer Res (2001) 61(1):256-260.
25. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ: Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev (1998) 12(11):1587-1592.
26. Engel ME, McDonnell MA, Law BK, Moses HL: Interdependent Smad and Jnk signaling in transforming growth factor-β-mediated transcription. J Biol Chem (1999) 274(52):37413-37420.
27. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S: Regulation of Smad signaling by protein kinase C. Faseb J (2001) 15(3):553-555.
28. Brown JD, DiChiara MR, Anderson KR, Gimbrone MA Jr, Topper JN: MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem (1999) 274(13):8797-8805.
29. 2+-calmodulin-dependent protein kinase II. Mol Cell Biol (2000) 20(21):8103-8111.
30. Luo K: Ski and SnoN: Negative regulators of TGF-β signaling. Curr Opin Genet Dev (2004) 14(1):65-70.
31. Pierce DF Jr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr, Moses HL: Mammary tumor suppression by transforming growth factor β 1 transgene expression. Proc Natl Acad Sci USA (1995) 92(10):4254-4258.
32. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ: TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell (1996) 86(4):531-542.
33. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL: Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 163(4):1539-1549.
34. Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M, Wang XJ: Distinct mechanisms of TGF-β1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 115(7):1714-1723.
35. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL: Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol Cell Biol (2003) 23(23):8691-8703.
36. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 103(2):197-206.
37. Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA (1990) 87(19):7678-7682.
38. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest (1993) 92(6):2569-2576.
39. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E: TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev (1996) 10(19):2462-2477.
40. Oft M, Heider KH, Beug H: TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol (1998) 8(23):1243-1252.
41. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, Balmain A: Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ (1998) 9(5):393-404.
42. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS: Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: The study of osteoporotic fractures. JAMA (2001) 285(22):2859-2863.
43. Shin A, Shu XO, Cai Q, Gao YT, Zheng W: Genetic polymorphisms of the transforming growth factor-β1 gene and breast cancer risk: A possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev (2005) 14(6):1567-1570.
44. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD et al: A transforming growth factorβ1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res (2003) 63(10):2610-2615.
45. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA (1996) 93(7):2909-2914.
46. Liau LM, Fakhrai H, Black KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-β antisense gene. Neurol Res (1998) 20(8):742-747.
47. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M: RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 64(20):7596-7603.
48. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P: Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev (2006) 17(1-2):129-139.
49. Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensiepen KH: Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety. Oligonucleotides (2005) 15(2):94-104.
50. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W: The effect of transforming growth factor-β 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg (1993) 78(6):944-951.
51. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ: Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res (2002) 62(16):4690-4695.
52. Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, Sun L: Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate (2005) 63(1):81-90.
53. Stander M, Naumann U, Dumitrescu L, Heneka M, Loschmann P, Gulbins E, Dichgans J, Weller M: Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther (1998) 5(9):1187-1194.
54. Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ: Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene (2002) 21(22):3541-3551.
55. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR et al: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 109(12):1607-1615.
56. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V et al: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 109(12):1551-1559.
57. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM: Soluble type II transforming growth factor-β receptor inhibits established murine malignant mesothelloma tumor growth by augmenting host antitumor immunity. Clin Cancer Res (2004) 10(17):5907-5918.
58. Kulkami AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA (1993) 90(2):770-774.
59. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M: Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res (2001) 7(9):2931-2940.
60. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, Korc M: Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther (2002) 1(3):161-167.
61. Rabbani ZN, Anscher MS, Zhang X, Chen L, Samulski TV, Li CY, Vujaskovic Z: Soluble TGFβ type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys (2003) 57(2):563-572.
62. Kontani K, Kajino K, Huangi CL, Fujino S, Taguchi O, Yamauchi A, Yokomise H, Ogasawara K: Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-β II receptor without active antigen-sensitization. Cancer Immunol Immunother (2006) 55(5):579-587.
63. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, Blanco G, Rodriguez C, Lechuga Mdel C, Greenwel P, Rojkind M et al: A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine (2003) 22(1-2):12-20.
64. Santiago B, Gutierrez-Canas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borras-Cuesta F, Pablos JL: Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 125(3):450-455.
65. Benigni A, Zoja C, Coma D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S et al: Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol (2003) 14(7):1816-1824.
66. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT: Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci (2003) 44(8):3394-3401.
67. Cambridge Antibody Technology Group plc: Cambridge Antibody Technology announces interim results for the six months ended 31 March 2005. Press Release (2005):May 16.
68. Cambridge Antibody Technology Group plc: Cambridge Antibody Technology announces preliminary results of second pivotal Trabio clinical trial: CAT drops glaucoma surgery drug after phase III failure. Press Release (2005):March 22.
69. Genzyme General: Genzyme General and Cambridge Antibody Technology to collaborate on development of human anti-TGFβ monoclonal antibodies. Press Release (2000): September 28.
70. Jachimczak P: TGFβ in cancer and other diseases, La Jolla, CA, USA. IDdb Meeting Report (2006): February 08-12.
71. Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, Richards SM, Garman RD: Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol (2003) 25(2):235-257.
72. Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM: Transforming the TGFβ pathway: Convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discovery Dev (2004) 7(4):437-445.
73. Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov (2004) 3(12):1011-1022.
74. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type 1 activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2002) 62(1):65-74.
75. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A et al: SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 64(21):7954-7961.
76. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A et al: Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res (2004) 10(22):7540-7546.
77. Oft M, Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 4(7):487-494.
78. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2005):doi: 10.1038/sj.onc.1208964.
79. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K: Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest (2005) 85(4):512-521.
80. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, Tsushima H, Matsuzawa Y: Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res (1992) 83(7):676-679.
81. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y: Positive correlation of plasma transforming growth factor-β 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett (1995) 89(1):45-48.
82. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y: High levels of transforming growth factor β 1 in patients with colorectal cancer: Association with disease progression. Gastroenterology (1996) 110(2):375-382.
83. Ito N, Kawata S, Tsushima H, Tamura S, Kiso S, Takami S, Igura T, Monnden M, Matsuzawa Y: Increased circulating transforming growth factor β1 in a patient with giant hepatic hemangioma: Possible contribution to an impaired immune function. Hepatology (1997) 25(1):93-96.
84. Barthelemy-Brichant N, David JL, Bosquee L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet-Mahieu L, Deneufbourg JM: Increased TGFβ1 plasma level in patients with lung cancer: Potential mechanisms. Eur J Clin Invest (2002) 32(3):193-198.
85. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor β1 and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res (2004) 10(6):1992-1999.
86. Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M: Targeting endogenous transforming growth factor β receptor signaling in Smad4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype. Cancer Res (2004) 64(15):5200-5211.
87. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 344(16):1196-1206.
88. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 342(2):69-77.
89. Lothe RA, Peitomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pyikkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO et al: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res (1993) 53(24):5849-5852.
90. Akhurst RJ: TGF β signaling in health and disease. Nat Genet (2004) 36(8):790-792.
91. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, Akhurst RJ: Mapping of a major genetic modifier of embryonic lethality in TGF β 1 knockout mice. Nat Genet (1997) 15(2):207-211.
92. Mao JH, Saunier EF, de Koning JP, McKinnon MM, Nakijama Higgins M, Nicklas K, Yang H-T, Balmain A, Akhurst RJ, Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci USA (2008):doi: 10.1073/pnas.0602581103.
93. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J: A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 13(5):759-764.
94. Cancer Drugs Research and Development - GTCBio's Third Annual Conference, San Francisco, CA, USA. IDdb Meeting Report (2008):February 9-10.
95. Schlingensiepen KH, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P, Kielmanowicz M, Niewel M, Zavadova E, Stauder G: The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. J Clin Oncol (2004) 22(14S):Abs 3132.
96. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S et al: Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem (2003) 46(19):3953-3956.
97. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL et al: Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg Med Chem Lett (2003) 13(24):4355-4359.
98. Cui Q, Lim SK, Zhao B, Hoffmann FM: Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene (2005) 24(24):3864-3874.
99. Callahan JF, Burgess JL, Fomwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA et al: Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J Med Chem (2002) 45(5):999-1001.
100. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN: SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 3(6):737-745.
101. DaCosta Byfield S, Major C, Laping NJ, Roberts AB: SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2004) 65(3):744-752.